Avidity Biosciences EBITDA Margin 2019-2022 | RNA
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Avidity Biosciences (RNA) over the last 10 years. The current EBITDA margin for Avidity Biosciences as of March 31, 2022 is .
| Avidity Biosciences EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.01B |
$-0.13B |
-1411.11% |
| 2021-12-31 |
$0.01B |
$-0.12B |
-1170.00% |
| 2021-09-30 |
$0.01B |
$-0.10B |
-950.00% |
| 2021-06-30 |
$0.01B |
$-0.08B |
-770.00% |
| 2021-03-31 |
$0.01B |
$-0.06B |
-677.78% |
| 2020-12-31 |
$0.01B |
$-0.04B |
-614.29% |
| 2020-06-30 |
$0.00B |
$-0.02B |
-525.00% |
| 2020-03-31 |
$0.00B |
$-0.02B |
-750.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.769B |
$0.009B |
|
Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.
|
